Target (CBDY) Capital Expenditures (2018 - 2026)
Target (CBDY) reported Capital Expenditures of $40055.0 for Q1 2026, up 43169.89% year-over-year from N/an in Q1 2025, and up 81844.9% quarter-over-quarter from -$49.0 in Q4 2025.
Target (CBDY) Capital Expenditures (2018 - 2026) Analysis & Trends
Target (CBDY) has 9 years of Capital Expenditures data on file, last reported at $40055.0 in Q1 2026.
- Capital Expenditures for Q1 2026 came in at $40055.0, up 43169.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $114775.0 (up 71.73% YoY), and the FY2025 annual result was $74627.0, up 7.46% from the prior year.
- Capital Expenditures grew to $40055.0 in Q1 2026 per CBDY's latest filing, from -$49.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $47575.0 in Q3 2025 and troughed at -$93.0 in Q1 2025.
- A 5-year average of $14156.5 and a median of $6725.0 in 2024 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2023 and 2025: Capital Expenditures jumped 418175.0% in 2023, then slumped 103.69% in 2025.
- A 5-year view of Capital Expenditures shows it stood at -$4.0 in 2022, then jumped by 418175.0% to $16723.0 in 2023, then tumbled by 59.79% to $6725.0 in 2024, then sank by 100.73% to -$49.0 in 2025, then soared by 81844.9% to $40055.0 in 2026.
- Business Quant data shows CBDY's Capital Expenditures at $40055.0 in Q1 2026, -$49.0 in Q4 2025, and $47575.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 168.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 110.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 100.80 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 9.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 51.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.09 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 8.83 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.04 Mn |
| 10 | Target | - | - | 191,787.00 | 40,055.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40,055.00 |
| Mar 31, 2026 | 40,055.00 |
| Dec 31, 2025 | -49.00 |
| Dec 31, 2025 | -49.00 |
| Sep 30, 2025 | 47,575.00 |
| Sep 30, 2025 | 47,575.00 |
| Jun 30, 2025 | 27,194.00 |
| Jun 30, 2025 | 27,194.00 |
| Mar 31, 2025 | -93.00 |
| Mar 31, 2025 | -93.00 |
| Dec 31, 2024 | 6,725.00 |
| Dec 31, 2024 | 6,725.00 |
| Sep 30, 2024 | 39,770.00 |
| Sep 30, 2024 | 39,770.00 |
| Jun 30, 2024 | 20,432.00 |
| Jun 30, 2024 | 20,432.00 |
| Mar 31, 2024 | 2,517.00 |
| Mar 31, 2024 | 2,517.00 |
| Dec 31, 2023 | 16,723.00 |
| Dec 31, 2023 | 16,723.00 |